A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
about
Developing strategies in the immunotherapy of leukemiasEvaluation of current cancer immunotherapy: hemato-oncologyK562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.Advances in gene therapy for malignant melanoma.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.Characterization of chronic myeloid leukemia stem cells.GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.The search for optimal treatment in relapsed and refractory acute myeloid leukemia.Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.Paradoxical decrease in the capture and lymph node delivery of cancer vaccine antigen induced by a TLR4 agonist as visualized by dual-mode imaging.GM-CSF-based cancer vaccines.Cytokines and antitumor immunity.Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.Cell-based immune therapy for metastatic renal cancer.Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines.Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.Haematological malignancies: at the forefront of immunotherapeutic innovation.An effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model.Vaccines in cancer: GVAX, a GM-CSF gene vaccine.A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model.Treatment of pulmonary metastatic tumors in mice using lentiviral vector-engineered stem cells.Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cellsGVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer.Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.Autologous CLL cell vaccination early after transplant induces leukemia-specific T cellsImmunotherapy for myeloid leukemias: current status and future directions.Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML).Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.The biological basis for immunotherapy in patients with chronic myelogenous leukemia.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.A bystander cell-based GM-CSF secreting vaccine synergized with a low dose of cyclophosphamide presents therapeutic immune responses against murine hepatocellular carcinoma.Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.Immune therapies for malignant mesothelioma.Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy.Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.
P2860
Q26996310-1CE30D35-2263-4688-93D4-6B44BA688C81Q27006179-5C9C7B50-0D81-42E9-94D8-30921ECD5692Q33584244-EB6F04B6-4F92-4CDD-9130-FC14A322C13DQ34119859-2BE402FC-B9BE-4503-B55F-A7A5EB99885CQ34315863-6F82B1E3-5ECF-49E6-9D8F-54D5C941373AQ34443802-44E5C947-08FF-4388-927A-911102A301E6Q34591128-BA2749BC-E811-46EA-B38B-342AC9F3BD70Q34630777-DAC796FE-FE14-4647-99CF-233166843069Q34887495-A37BBEB9-CE3B-4CF8-B83D-45993BB34EA6Q34980976-19377F87-B51C-494E-B1BB-15D0A2C7CD15Q34995056-C23EB061-A957-497E-BD1A-6388144225D0Q35005952-77F8E250-024B-4B65-8A2C-B0F84E82DE43Q35142319-8DAF078E-96B7-419D-B7B9-6FEFA24B6F40Q35562729-CC629B6C-35AB-4245-B90E-9AAAA3B52814Q35611888-A27E1C4C-37E1-47EE-B35A-F8869C1F7B12Q35809463-51043A3C-0CB4-490E-952A-BDFFD49414A5Q35835489-B3254D7F-DE87-4D98-9BD1-B5314F179210Q35880618-62131F61-66B1-4729-A388-B1B3C77DC63BQ36145145-B1EBFC72-17B7-47C9-8655-752CF5790AE6Q36198632-618BA61B-05F1-42A1-BA46-131484773DC2Q36394506-BAF2120B-44CC-4601-88CC-4E8164DCFE52Q36482614-2C0AC35E-0DFB-4650-BB56-63D01EDBC26DQ36884975-D672104B-E66E-4D02-AF48-EFEDD41B76B4Q36915913-74BB737A-B790-4B62-89FF-8068C32DE5C5Q37012084-664AD0B8-2E4D-4837-BC9D-3CF5BF79979CQ37014134-AA3D5981-C33C-4060-A44C-0C123DDF6B83Q37123927-4C3AD14C-DB96-40D6-ACEC-2F050B9D2EC2Q37194498-DEF6C88F-A93D-461A-B51A-D3DA4F011472Q37334588-8E695015-0CF8-4761-96E6-6B98AA08C07AQ37355213-A274C1B3-36FF-4A14-80FB-61F267F13FA8Q37428671-CA36A1C4-9170-4A00-B1BB-21BDBD7E5D0CQ37517482-2CD257F5-B882-4916-A318-49F57CE0F6EBQ37729647-21B97D2D-63D1-41B6-A37A-8FB7B2AF8EF9Q38025094-3147F9CD-F094-4D55-A30E-129BB843B1A3Q38212149-304818E1-A6FD-49B0-BF04-9CEB843F75B4Q39543940-59865D37-B335-42A8-8DD7-49829964B76CQ40330261-A657FA52-A49C-4F33-8666-09508FFCA98EQ41545207-EB8E4160-A194-476F-A1C5-B1E597A7852CQ51031723-31D150EB-1A7B-4384-881D-B3B83EFD20F5
P2860
A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
A universal granulocyte-macrop ...... ous tumor cell-based vaccines.
@en
type
label
A universal granulocyte-macrop ...... ous tumor cell-based vaccines.
@en
prefLabel
A universal granulocyte-macrop ...... ous tumor cell-based vaccines.
@en
P2093
P1433
P1476
A universal granulocyte-macrop ...... ous tumor cell-based vaccines.
@en
P2093
E M Sotomayor
H I Levitsky
I Borrello
P304
P356
10.1089/10430349950017347
P577
1999-08-01T00:00:00Z